FMS vs. MDLN: Fresenius Medical Care vs. Medline Stock Comparison

Company Profile

Fresenius Medical Care (FMS) and Medline (MDLN) both fall under the Health Care Equipment & Services industry group, but FMS is classified in Health Care Providers & Services while MDLN is classified in Health Care Equipment & Supplies.

Fresenius Medical Care (FMS) has been public since September 17, 1996, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Medline (MDLN) trades as ordinary local shares, while Fresenius Medical Care (FMS) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Fresenius Medical Care (FMS) has a non-negative beta of 0.77.

Risk-Adjusted Performance

Risk-Return Positioning

Both FMS and MDLN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Both Fresenius Medical Care (FMS) at 7.84% and Medline (MDLN) at 4.85% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Both Fresenius Medical Care (FMS) at 4.22% and Medline (MDLN) at 1.85% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Both Fresenius Medical Care (FMS) at 9.63% and Medline (MDLN) at 5.22% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

Profitability Metrics

Growth

Only one side can be read here: Fresenius Medical Care (FMS) reports revenue growth of 1.51%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Both companies show strong earnings momentum, but Medline (MDLN) at 117.38% is the standout with EPS growth above its industry range; Fresenius Medical Care (FMS) at 83.61% also sits in the top quartile.

Growth Metrics

Financial Strength

Medline (MDLN) at 4.04 carries current ratio above its industry’s typical mid-range, while Fresenius Medical Care (FMS) at 0.99 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Both Fresenius Medical Care (FMS) at 0.79 and Medline (MDLN) at 0.65 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Medline (MDLN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Fresenius Medical Care (FMS) reports a yield of 6.30%, ranking against industry peers normally.

Medline (MDLN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Fresenius Medical Care (FMS) reports a payout of 50.14%, ranking against industry peers normally.

Dividend Metrics

Valuation

Fresenius Medical Care (FMS) at 13.53 sits in the cheaper P/E ratio quartile, while Medline (MDLN) at 90.09 trades above its peer range — a wide earnings-valuation gap relative to industry peers.

Fresenius Medical Care (FMS) at 0.62 sits in the cheaper P/S ratio quartile while Medline (MDLN) at 1.70 prices around its industry’s middle — FMS costs less per dollar of sales, though read it alongside growth and margins.

Fresenius Medical Care (FMS) at 0.85 sits in the lower P/B ratio quartile against book while Medline (MDLN) at 2.95 is valued near its industry’s middle — FMS is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics